Best Stocks Under $3 Right Now It can be difficult to find a deal in the stock market regardless of current market conditions. For the last decade, stocks have traded well above historical average P/E ratios. Fortunately there are still a handful of undervalued stocks in corners of the market that most investors ignore. This page lists cheap stocks that have a share price of $3.00 (3 dollars) or less and consisently-receive "buy" and "strong buy" ratings from Wall Street's top-rated research analysts. OverviewStocks Under $0.05Stocks Under $0.10Stocks Under $0.25Stocks Under $0.50Stocks Under $1Stocks Under $2Stocks Under $3Stocks Under $5Stocks Under $10Stocks Under $20Stocks Under $30Stocks Under $50Stocks On Sale 1. OS Therapies NYSE:OSTX$1.98 -0.02 (-1.00%) As of 03:40 PM EasternOS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. More about OS TherapiesMarket Capitalization$42.90 millionConsensus RatingBuyConsensus Price Target$18.00 (+809.1% Upside)Volume319,435 sharesAverage Volume483,563 sharesToday's Range$1.80▼$2.10 Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. 2. Stardust Power NASDAQ:SDST$0.50 +0.00 (+0.95%) As of 03:29 PM EasternStardust Power Inc is a vertically-integrated lithium refinery that engages in producing battery-grade lithium. The company was founded in 2022 and is based in Greenwich, Connecticut.Market Capitalization$28.95 millionConsensus RatingBuyConsensus Price Target$5.11 (+922.5% Upside)Volume169,965 sharesAverage Volume347,702 sharesToday's Range$0.49▼$0.513. Denison Mines NYSEAMERICAN:DNN$1.42 -0.01 (-0.35%) As of 03:41 PM EasternDenison Mines Corp. engages in the acquisition, exploration, and development of uranium bearing properties in Canada. Its flagship project is the Wheeler River uranium project covering an area of approximately 300,000 hectares located in the Athabasca Basin region in northern Saskatchewan. More about Denison MinesMarket Capitalization$1.27 billionP/E Ratio-141.50Consensus RatingBuyConsensus Price Target$3.00 (+112.0% Upside)Volume54.62 million sharesAverage Volume30.24 million shares4. OnKure Therapeutics NASDAQ:OKUR$2.52 -0.01 (-0.40%) As of 03:24 PM EasternOnKure Therapeutics, Inc engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. More about OnKure TherapeuticsMarket Capitalization$33.86 millionP/E Ratio-0.21Consensus RatingBuyConsensus Price Target$32.33 (+1,183.1% Upside)Volume27,913 sharesAverage Volume81,974 shares5. Cardiol Therapeutics NASDAQ:CRDL$1.10 -0.05 (-4.35%) As of 03:40 PM EasternCardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. More about Cardiol TherapeuticsMarket Capitalization$90.87 millionP/E Ratio-2.82Consensus RatingBuyConsensus Price Target$8.40 (+663.6% Upside)Volume148,909 sharesAverage Volume382,062 shares6. GeoVax Labs NASDAQ:GOVX$1.00 0.00 (-0.15%) As of 03:37 PM EasternGeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. More about GeoVax LabsMarket Capitalization$13.81 millionP/E Ratio-0.18Consensus RatingBuyConsensus Price Target$12.90 (+1,192.8% Upside)Volume194,574 sharesAverage Volume589,966 shares7. Quince Therapeutics NASDAQ:QNCX$1.07 -0.06 (-5.31%) As of 03:23 PM EasternQuince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. More about Quince TherapeuticsMarket Capitalization$47.21 millionP/E Ratio-0.86Consensus RatingBuyConsensus Price Target$8.00 (+647.7% Upside)Volume74,904 sharesAverage Volume248,156 shares8. Reviva Pharmaceuticals NASDAQ:RVPH$0.87 -0.01 (-1.28%) As of 03:38 PM EasternReviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. More about Reviva PharmaceuticalsMarket Capitalization$40.47 millionP/E Ratio-0.78Consensus RatingBuyConsensus Price Target$10.00 (+1,055.0% Upside)Volume221,214 sharesAverage Volume1.13 million shares9. Immunic NASDAQ:IMUX$1.00 -0.28 (-21.88%) As of 03:40 PM EasternImmunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. More about ImmunicMarket Capitalization$95.82 millionP/E Ratio-0.81Consensus RatingBuyConsensus Price Target$13.20 (+1,220.0% Upside)Volume8.05 million sharesAverage Volume671,669 shares10. Nkarta NASDAQ:NKTX$2.12 +0.17 (+8.72%) As of 03:40 PM EasternNkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. More about NkartaMarket Capitalization$150.43 millionP/E Ratio-1.13Consensus RatingBuyConsensus Price Target$14.86 (+600.8% Upside)Volume381,650 sharesAverage Volume1.09 million shares11. Rezolve AI NASDAQ:RZLV$2.26 -0.17 (-7.00%) As of 03:40 PM EasternRezolve Ai Ltd. operates in the mobile commerce industry with its cutting-edge engagement platform powered by artificial intelligence and machine learning. More about Rezolve AIMarket Capitalization$389.13 millionConsensus RatingBuyConsensus Price Target$6.00 (+165.5% Upside)Volume5.04 million sharesAverage Volume5.24 million sharesToday's Range$2.17▼$2.3312. Mereo BioPharma Group NASDAQ:MREO$2.58 +0.06 (+2.38%) As of 03:40 PM EasternMereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. More about Mereo BioPharma GroupMarket Capitalization$410.22 millionP/E Ratio-43.00Consensus RatingBuyConsensus Price Target$7.71 (+199.0% Upside)Volume662,176 sharesAverage Volume1.10 million shares13. Lavoro NASDAQ:LVRO$2.71 -0.21 (-7.19%) As of 03:37 PM EasternLavoro Limited operates as an agricultural inputs retailer. The company operates through three segments: Brazil Cluster, LATAM Cluster, and Crop Care Cluster. More about LavoroMarket Capitalization$316.01 millionP/E Ratio-1.66Consensus RatingBuyConsensus Price Target$5.13 (+89.1% Upside)Volume4,218 sharesAverage Volume7,757 shares14. Western Copper & Gold NYSE:WRN$1.11 +0.00 (+0.30%) As of 03:24 PM EasternWestern Copper & Gold Corp. operates as an exploration stage company, which engages in the acquisition, exploration, and future development of mineral resource properties. More about Western Copper & GoldMarket Capitalization$221.66 millionP/E Ratio-55.42Consensus RatingBuyConsensus Price Target$4.25 (+283.5% Upside)Volume240,743 sharesAverage Volume332,966 shares15. Orchestra BioMed NASDAQ:OBIO$2.94 +0.41 (+16.21%) As of 03:40 PM EasternOrchestra BioMed Holdings, Inc operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. More about Orchestra BioMedMarket Capitalization$112.64 millionP/E Ratio-1.83Consensus RatingBuyConsensus Price Target$15.00 (+410.2% Upside)Volume606,486 sharesAverage Volume151,974 shares16. Ur-Energy NYSEAMERICAN:URG$0.76 +0.01 (+0.69%) As of 03:41 PM EasternUr-Energy Inc engages in the acquisition, exploration, development, and operation of uranium mineral properties. The company holds interests in 12 projects located in the United States. More about Ur-EnergyMarket Capitalization$276.50 millionP/E Ratio-5.84Consensus RatingBuyConsensus Price Target$2.30 (+202.9% Upside)Volume1.87 million sharesAverage Volume4.17 million shares17. HIVE Digital Technologies NASDAQ:HIVE$1.68 -0.05 (-2.62%) As of 03:38 PM EasternHIVE Digital Technologies Ltd. operates as a cryptocurrency mining company in Canada, Sweden, and Iceland. The company engages in the mining and sale of digital currencies, including Ethereum Classic, Bitcoin, and other coins. More about HIVE Digital TechnologiesMarket Capitalization$285.45 millionP/E Ratio-33.50Consensus RatingBuyConsensus Price Target$7.64 (+356.3% Upside)Volume7.05 million sharesAverage Volume6.23 million shares18. Lucid Diagnostics NASDAQ:LUCD$1.29 +0.03 (+2.00%) As of 03:40 PM EasternLucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. More about Lucid DiagnosticsMarket Capitalization$135.44 millionP/E Ratio-1.13Consensus RatingBuyConsensus Price Target$3.50 (+172.3% Upside)Volume945,820 sharesAverage Volume470,462 shares19. Genelux NASDAQ:GNLX$2.70 -0.27 (-9.09%) As of 03:38 PM EasternGenelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. More about GeneluxMarket Capitalization$93.43 millionP/E Ratio-2.84Consensus RatingBuyConsensus Price Target$18.25 (+575.9% Upside)Volume137,677 sharesAverage Volume209,041 shares20. Electrovaya NASDAQ:ELVA$2.65 +0.01 (+0.38%) As of 03:19 PM EasternElectrovaya Inc engages in the design, development, manufacture, and sale of lithium-ion batteries, battery management systems, and battery-related products for energy storage, clean electric transportation, and other specialized applications in North America. More about ElectrovayaMarket Capitalization$106.28 millionP/E Ratio-66.25Consensus RatingBuyConsensus Price Target$6.10 (+130.2% Upside)Volume15,859 sharesAverage Volume51,232 shares21. Akebia Therapeutics NASDAQ:AKBA$2.42 -0.01 (-0.41%) As of 03:34 PM EasternAkebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. More about Akebia TherapeuticsMarket Capitalization$571.68 millionP/E Ratio-10.52Consensus RatingBuyConsensus Price Target$6.63 (+173.8% Upside)Volume2.74 million sharesAverage Volume2.80 million shares22. Ceragon Networks NASDAQ:CRNT$2.17 -0.02 (-0.91%) As of 03:39 PM EasternCeragon Networks Ltd., together with its subsidiaries, provides wireless transport solutions for cellular operators and other wireless service providers in North America, Europe, Africa, the Asia Pacific, the Middle East, India, and Latin America. More about Ceragon NetworksMarket Capitalization$192.98 millionP/E Ratio8.04Consensus RatingBuyConsensus Price Target$6.38 (+193.8% Upside)Volume395,560 sharesAverage Volume1.05 million shares23. NRx Pharmaceuticals NASDAQ:NRXP$2.08 +0.02 (+0.97%) As of 03:39 PM EasternNRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. More about NRx PharmaceuticalsMarket Capitalization$35.19 millionP/E Ratio-0.97Consensus RatingBuyConsensus Price Target$28.50 (+1,270.2% Upside)Volume231,294 sharesAverage Volume439,509 shares24. Vigil Neuroscience NASDAQ:VIGL$2.08 +0.17 (+8.59%) As of 03:40 PM EasternVigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. More about Vigil NeuroscienceMarket Capitalization$102.42 millionP/E Ratio-1.01Consensus RatingBuyConsensus Price Target$16.25 (+679.4% Upside)Volume103,909 sharesAverage Volume474,412 shares25. FibroBiologics NASDAQ:FBLG$1.10 +0.06 (+5.29%) As of 03:40 PM EasternFibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. More about FibroBiologicsMarket Capitalization$41.32 millionP/E Ratio-3.22Consensus RatingBuyConsensus Price Target$13.00 (+1,087.2% Upside)Volume159,772 sharesAverage Volume291,070 shares More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hims & Hers Stock Soars on Novo Nordisk Collaboration 3 Dividend Kings Outshining the Market in 2025 Tesla's Band-Aid Has Been Ripped Off: Rally Mode Engaged Amazon's Earnings Will Make or Break the Stock's Comeback Why D-Wave's Project With Davidson Is a Game-Changer For Quantum NXP Semiconductors: A Buy-and-Hold Stock in the Buy Zone Joby Aviation Shares Eye Breakout After Transition Flight Win Altria’s Resilient Strategy Keeps It a Top Dividend Play in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
